In a double-blind, placebo-controlled trial of 326 patients, 4 patients suffered serious adverse events and 61% became resedated following the use of flumazenil.
However, a double-blind comparison could still yield claims of perceived differences and thus lack of transparency, even though such claims would be in error.
One randomized double-blind placebo-controlled study was conducted in infants who manifested atopic eczema during exclusive breast-feeding and who had no exposure to any infant or substitute formula.
